Publications
- The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs (nature.com) Mapletoft JPJ, St-Onge RJ, Guo B, Butler P, Masilamani TJ, D’Costa L, Pritzker LB, Parissenti AM. (2020). The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs. Scientific Reports 10:8671.
- RNA disruption indicates CHOP therapy efficacy in canine lymphoma (nih.gov) Parissenti AM, Pritzker LB, Guo B, Narendrula R, Wang XW, Lin LL, Skowronski K, Bienzle D, Woods JP, Pritzker KPH, Coomber BL. (2019). RNA disruption indicates CHOP therapy efficacy in canine lymphoma. BMC Vet Research 15:453.
- RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Toomey S, Eustace AJ, Pritzker, L.B.; Pritzker, K.P.H.; Fay J, O’Grady A, Cummins R, O’Connor D, Young, L, Kay E, O’Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT
NCI J Natl Cancer Inst (2016) 108 (8) djw111, First published online July 4, 2016 , doi:10.1093/jnci/djw111 - RNA Disruption Assay (RDA) as a biomarker of pCR in NeoAdjuvant trastuzumab-treated HER2-positive breast cancer Trudeau, M. E.
JNCI J Natl Cancer Inst (2016) 108 (8): djw105 First published online July 4, 2016, doi:10.1093/jnci/djw105 - RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines
Narendrula R, Mispel-Beyer K, Guo B, Parissenti AM, Pritzker LB, Pritzker K, Masilamani T, Wang X, Lanner C.
BMC Cancer (2016) 16:146. Published online, Febrary 24, 2016
DOI 10.1186/s12885-016-2197-1 - Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy
Parissenti, A.M.; Guo, B.; Pritzker,L.B.; Pritzker, K. P. H.; Wang, X.; Zhu, M.; Shepherd, L.; Trudeau, M. A.
Breast Cancer Research and Treatment DOI 10.1007/s10549-015-3498-9 Published online July 25,2015 August 2015, Volume153(Issue1) Page p.135To-144 - RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy
Pritzker, K.P.H.; Pritzker,L. B.; Generali, D.; Bottini, A.; Cappelletti, M. R.; Guo, B.; Parissenti, A. M.; Trudeau, M.E.
JNCI Monographs 2015 2015 (51): 76-80
doi: 10.1093/jncimonographs/lgv015 - Novel anti-hormonal agent, AT-001, impairs androgen-independent prostate tumor growth by suppressing the relaxin signaling pathway
Anton Neschadim, Laura B. Pritzker, Kenneth P.H. Pritzker, Donald R. Branch, Alastair J.S. Summerlee, John Trachtenberg, Joshua D. Silvertown
Endocrine- Related Cancer 2014 21;3 459 -471 ERC-14-0088.R1 - Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy
Chiara Foroni, Carla Strina, Manuela Milani, Mariarosa Cappelletti, Claudia Fumarola, Mara Bonelli, Ramona Bertoni, Giuseppina Ferrero, Elena Takano, Daniele Andrei*, Sergio Venturini, Giulia Brugnol, Pier Giorgio Petronini, Roberto Giardini, Laura Pritzker, Kenneth Pritzker ,Amadeo Parissenti, Alfredo Berruti, Stephen B Fox, Alberto Bottini, Daniele Generali
Breast Cancer Research and Treatment 2014, 144 113-121 - Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients
Amadeo M. Parissenti, Judy-Anne W. Chapman, Harriette J. Kahn,
Baoqing Guo, Lei Han, Patti O’Brien, Mark P. Clemons, Roberta Jong,
Rebecca Dent, Barbara Fitzgerald, Kathleen I. Pritchard, Lois E. Shepherd,
Maureen E. Trudeau
Breast Cancer Research and Treatment 2010:119, 347-356